New York, NY -- (SBWIRE) -- 03/03/2013 -- Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) recently announced the receipt of guidance from the Director of the Office of New Drugs at FDA which provides Chelsea a new regulatory path forward for Northera.
This guidance has led us to a decision to resubmit a New Drug Application for Northera for the treatment of symptomatic neurogenic orthostatic hypotension which in turn has the potential to yield an approval decision by year-end.
Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.
It is primarily developing Northera (droxidopa), a novel therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine-ß-hydroxylase, deficiency, and non-diabetic autonomic neuropathy.
Find out more on CHTP by getting the full trend analysis report here: http://www.monstertradingalerts.com/market-scan/?symbol=CHTP
Radian Group Inc. (NYSE:RDN) recently announced that the underwriters of its previously announced concurrent public offerings of common stock and convertible senior notes due 2019 have exercised in full their options to purchase an additional 5.1 million shares of common stock and an additional $50 million principal amount of notes from the Company at the public offering price, less underwriting discounts and commissions.
As a result, the Company expects to issue a total of 39.1 million shares and $400 million principal amount of notes and to receive aggregate net proceeds, after underwriting discounts and commissions and estimated offering expenses, of approximately $299.5 million from the common stock offering and $389.8 million from the convertible senior notes offering. The offerings are expected to close on March 4, 2013, subject to customary closing conditions.
Find out where RDN could be headed by getting the full trend analysis report here: http://www.monstertradingalerts.com/market-scan/?symbol=RDN
MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www. MonsterTradingAlerts.com
MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/
Alexander K. Neumann
Monster Trading Alerts
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)